The knockdown of MALAT1 in trastuzumab-resistant BC HER2+ cells was previously shown to limit cell invasion, while simultaneously enhancing the sensitivity of BC cells to trastuzumab [9]. This evidence concerns the gene ERBB2 and breast cancer.